Loading clinical trials...
Loading clinical trials...
Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do not know why or which patients will benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients that may benefit from medicines that attack HER2. This is experimental.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
November 6, 2014
Primary Completion Date
June 30, 2020
Completion Date
June 30, 2020
Last Updated
June 18, 2021
49
ACTUAL participants
89Zr-trastuzumab
RADIATION
PET/CT scan
DEVICE
89Zr-pertuzumab
RADIATION
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
NCT06708910
NCT06958627
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01785420